Irinotecan therapy in adults with recurrent or progressive malignant glioma

Journal of Clinical Oncology

Volumn 17, Issue 5, 1999, Pages 1516-1525

  Friedman, Henry S ^a   Petros, William P ^a   Friedman, Allan H ^a   Schaaf, Larry J ^a   Kerby, Tracy ^a   Lawyer, Jennifer ^a   Parry, Mary ^a   Houghton, Peter J ^a   Lovell, Shelley ^a   Rasheed, Karima ^a   Cloughsey, Tim ^a   Stewart, Elizabeth S ^a   Colvin, O Michael ^a   Provenzale, James M ^a   McLendon, Roger E ^a   Bigner, Darell D ^a   Cokgor, Ilkcan ^a   Haglund, Michael ^a   Rich, Jeremy ^a   Ashley, David ^a   Malczyn, Joseph ^a   Elfring, Gary L ^a   Miller, Langdon L ^a   more..

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; 7 ETHYL 10 HYDROXYCAMPTOTHECIN GLUCURONIDE; DRUG METABOLITE; IRINOTECAN; UNCLASSIFIED DRUG;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; FEMALE; GLIOBLASTOMA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR GROWTH;

EID: 0032945307     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.5.1516     Document Type: Article

References (60)

1. Chang CH, Horton J, Schoenfeld D, et al: Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. Cancer 52:997-1007, 1983
2. Shapiro WR: Therapy of adult malignant brain tumors: What have the clinical trials taught us? Semin Oncol 13:38-45, 1986
3. Salcman M: Survival in glioblastoma: Historical perspective. Neurosurgery 7:435-439, 1980
4. Levin VA, Wara WM, Davis RL, et al: NCOG protocol 6G91: Seven-drug chemotherapy and irradiation for patients with glioblastoma multiforme. Cancer Treat Rep 70:739-744, 1986
5. Macdonald DR, Cascino TL, Schold SC Jr, et al: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277-1280, 1990
6. Cairncross JG, Macdonald DR, Pexman JHW, et al: Steroid-induced CT changes in patients with recurrent malignant glioma. Neurology 38:724-726, 1988
7. Watling CJ, Lee DH, Macdonald DR, et al: Corticosteroid-induced magnetic resonance imaging changes in patients with recurrent malignant glioma. J Clin Oncol 12:1886-1889, 1994
8. Glantz MJ, Cole BF, Friedberg MH, et al: A randomized, blinded, placebo-controlled trial of divalproex sodium prophylaxis in adults with newly diagnosed brain tumors. Neurology 46:985-991, 1996
9. Kirby S, Macdonald D, Fisher B, et al: Pre-radiation chemotherapy for malignant glioma in adults. Can J Neurol Sci 23:123-127, 1996
10. Brandes AA, Rigon A, Zampieri P, et al: Early chemotherapy and concurrent radio-chemotherapy in high grade glioma. J Neurooncol 30:247-255, 1996
11. Levin VA, Gutin PH, Leibel S: Neoplasms of the central nervous system, in DeVita VT Jr, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology (ed 4). Philadelphia, PA, Lippincott, 1993, pp 1679-1738
12. Brandes AA, Fiorentino MV: The role of chemotherapy in malignant glioma: An overview. Cancer Invest 14:551-559, 1996
13. Kornblith PL, Walker M: Chemotherapy for malignant gliomas. J Neurosurg 68:1-17, 1988
14. Fine HA: The basis for current treatment recommendations for malignant gliomas. J Neurooncol 20:111-120, 1994
15. Mahaley MS Jr: Neuro-oncology index and review (adult primary brain tumors). J Neurooncol 11:85-147, 1991
16. Slichenmyer WJ, Rowinsky EK, Grochow LB, et al: Camptothecin analogues: Studies from The Johns Hopkins Oncology Center. Cancer Chemother Pharmacol 34:53-57, 1994
17. Pommier Y, Tanizawa A, Kohn KW: Mechanisms of topoisomerase I inhibition by anticancer drugs, in Liu LF (ed): Advances in Pharmacology. New York, NY, Academic Press, 1994, pp 73-92
18. Kono A, Hara Y: Conversion of CPT-11 into SN-38 in human tissues. Jpn J Cancer Chemother 18:2175-2178, 1991
19. Kawato Y, Aonuma M, Hirota Y, et al: Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 51:4187-4191, 1991
20. Yoshida A, Ueda T, Wano Y, et al: DNA damage and cell killing by camptothecin and its derivative in human leukemia HL-60 cells. Jpn J Cancer Res 84:566-573, 1993
21. Tanizawa A, Fujimori A, Fijimori Y, et al: Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. J Natl Cancer Inst 86:836-842, 1994
22. Gupta E, Mick R, Ramirez J, et al: Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients. J Clin Oncol 15:1502-1510, 1997
23. Rivory LP, Robert J: Identification and kinetics of a β-glucuronide metabolite of SN-38 in human plasma after administration of the camptothecin derivative irinotecan. Cancer Chemother Pharmacol 36:176-179, 1995
24. Rivory LP, Haaz M-C, Canal P, et al: Pharmacokinetic interrelationships of irinotecan (CPT-11) and its three major plasma metabolites in patients enrolled in phase I/II trials. Clin Cancer Res 3:1261-1266, 1997
25. Rivory LP, Riou JF, Haaz MC, et al: Identification and properties of a major plasma metabolite of irinotecan (CPT-11) isolated from the plasma of patients. Cancer Res 56:3689-3694, 1996
26. Haaz MC, Rivory LP, Riche C, et al: Metabolism of irinotecan (CPT-11) by human hepatic microsomes: Participation of cytochrome P-450 3A and drug interactions. Cancer Res 58:468-472, 1998
27. Camptosar brand of irinotecan hydrochloride injection [package insert]. Kalamazoo, MI, Pharmacia & Upjohn Co, 1997
28. Hare CB, Elion GB, Houghton PJ, et al: Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against pediatric and adult central nervous system tumor xenografts. Cancer Chemother Pharmacol 39:187-191, 1997
29. Coggins CA, Elion GB, Houghton PJ, et al: Enhancement of irinotecan (CPT-11) activity against central nervous system tumor xenografts by alkylating agents. Cancer Chemother Pharmacol 41:485-490, 1998
30. Houghton PJ, Cheshire PJ, Hallman JD II, et al: Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol 36:393-403, 1995
31. Schaaf L, Ichhpurani N, Elfring G, et al: Influence of age on the pharmacokinetics of irinotecan (CPT-11) and its metabolites, SN-38 and SN-38 glucuronide (SN-38G), in patients with previously treated colorectal cancer. Proc Am Soc Clin Oncol 16:202a, 1997 (abstr 708)
32. Vertosick FT Jr, Selker RG, Pollack IF, et al: The treatment of intracranial malignant gliomas using orally administered tamoxifen therapy: Preliminary results in a series of "failed" patients. Neurosurgery 30:897-902, 1992
33. Couldwell WT, Weiss MH, DeGiorgio CM, et al: Clinical and radiographic response in a minority of patients with recurrent malignant gliomas treated with high-dose tamoxifen. Neurosurgery 32:485-489, 1993
34. Levin VA, Wara WM, Davis RL, et al: Phase III comparison of BCNU and the combination of procarbazine, CCNU, and vincristine administered after radiation therapy with hydroxyurea for malignant gliomas. J Neurosurg 63:218-223, 1985
35. Levin VA, Silver P, Hannigan J, et al: Superiority of postradiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. Int J Radiat Oncol Biol Phys 18:321-324, 1990
36. Eagan RT, Childs DS, Layton DD, et al: Dianhydrogalactitol and radiation therapy: Treatment of supratentorial glioma. JAMA 24:2046-2050, 1979
37. Garrett MJ, Hughes HJ, Freeman LS: A comparison of radio-therapy alone with radiotherapy and CCNU in cerebral glioma. Clin Oncol 4:71-76, 1978
38. Solero CL, Monfardini S, Brambilla C, et al: Controlled study with BCNU vs CCNU as adjuvant chemotherapy following surgery plus radiotherapy for glioblastoma multiforme. Cancer Clin Trials 1979:43-48, 1979
39. Walker MD, Green SB, Byar DP, et al: Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant gliomas after surgery. N Engl J Med 303:1323-1329, 1980
40. Rothenberg ML: CPT-11: An original spectrum of clinical activity. Semin Oncol 23:21-26, 1996
41. Nakatsu S, Kondo S, Kondo Y, et al: Induction of apoptosis in multi-drug resistant (MDR) human glioblastoma cells by SN-38, a metabolite of the camptothecin derivative CPT-11. Cancer Chemother Pharmacol 39:417-423, 1997
42. Von Hoff DD, Rothenberg ML, Pitot HC, et al: Irinotecan (CPT-11) therapy for patients with previously treated metastatic colorectal cancer (CRC): Overall results of PDA-reviewed pivotal US clinical trials. Proc Am Soc Clin Oncol 16:228a, 1997 (abstr 803)
43. Rothenberg ML, Eckardt JR, Kuhn JG, et al: Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 14:1128-1135, 1996
44. Pitot HC, Wender DB, O'Connell MJ, et al: A phase II trial of irinotecan in patients with metastatic colorectal carcinoma. J Clin Oncol 15:2910-2919, 1997
45. Pazdur R, Zinner R, Rothenberg ML, et al: Age as a risk factor in irinotecan treatment of 5-FU-refractory colorectal cancer. Proc Am Soc Clin Oncol 16:260a, 1997 (abstr 921)
46. Fetell MR, Grossman SA, Fisher JD, et al: Pre-irradiation paclitaxel in glioblastoma multiforme: Efficacy, pharmacology, and drug interactions. J Clin Oncol 9:3121-3128, 1997
47. Kuhn J, Rizzo J, Chang S, et al: Effects of anticonvulsants (Acs) on the pharmacokinetics (PK) and metabolic profile of paclitaxel. Proc Am Soc Clin Oncol 16:224a, 1997 (abstr 787)
48. Zamboni WC, Gajjar AJ, Heideman RL, et al: Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma. Clin Cancer Res 4:783-789, 1998
49. Grossman SA, Hochberg F, Fisher J, et al: Increased 9-aminocamptothecin (9-AC) dose requirements in patients on anticonvulsants (AC). Proc Am Soc Clin Oncol 16:389a, 1997 (abstr 1387)
50. Stewart CF, Baker SD, Crom WR, et al: Clinical pharmacokinetics of topotecan (T) in children with cancer. Proc Am Assoc Cancer Res 34:395, 1995
51. Brierley CH, Senafi SB, Clarke D, et al: Regulation of the human bilirubin UDP-glucuronosyltransferase gene. Adv Enzyme Reg 36:85-97, 1996
52. Sutherland L, Ebner T, Burchell B: The expression of UDP-glucuronosyltransferases of the UGT1 family in human liver and kidney and in response to drugs. Biochem Pharmacol 45(2):295-301, 1993
53. Doostdar H, Grant MH, Melvin WT, et al: The effects of inducing agents on cytochrome P450 and UDP-glucuronyltransferase activities in human HEPG2 hepatoma cells. Biochem Pharmacol 46(4):629-635, 1993
54. Gupta E, Wang X, Ramirez J, et al: Modulation of glucuronidation of SN-38, the active metabolite of irinotecan, by valproic acid and phenobarbital. Cancer Chemother Pharmacol 39:440-444, 1997
55. Rendic S, Di Carlo FJ: Human cytochrome P450 enzymes: A status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev 29:413-580, 1997
56. Fleishaker J, Pearson L, Peters G: Phenytoin causes a rapid increase in 6β-hydroxy-cortisol urinary excretion in humans: A putative measure of CYP3A induction. J Pharm Sci 84:292-294, 1995
57. Fardel O, Lecureur V, Guillouzo A: Regulation of dexamethasone of P-glycoprotein expression in cultured rat hepatocytes. FEBS Letters 372:189-193, 1993
58. Schuetz EG, Beck WT, Schuetz JD: Modulators and substrates of P-glycoprotein and cytochrome P4503A up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol 49:311-318, 1996
59. Chu XY, Kato Y, Niinuma K, et al: Multispecific organic anion transporter is responsible for the biliary excretion of the camptothecin derivative irinotecan and its metabolites in rats. J Pharmacol Exp Ther 281:304-314, 1997
60. Chu XY, Kato Y, Sugiyama Y: Multiplicity of biliary excretion mechanisms for irinotecan, CPT-11, and its metabolites in rats. Cancer Res 57:1934-1938, 1997